BIT Biotron Limited
—Mkt Cap: —P/E: —1d ago
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 cli…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value2.78M USD
Revenue (TTM)363.42K USD
Gross Profit363.42K USD
Net Income (TTM)-2.37M USD
Revenue/Share0.00 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000BIT4
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.58
EV/Revenue7.64
P/S10.59
P/B2.00
EPS (TTM)0.00
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-118.85%
EBITDA Margin-295.55%
Profit Margin-288.72%
ROE1408.23%
ROA-696.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.23M USD
CapEx (TTM)—
FCF Margin-111.99%
FCF Yield—
Net Debt-1.07M USD
Net Debt/EBITDA1.00
Balance Sheet
Debt/Equity-0.03
Current Ratio1.94
Quick Ratio1.92
Book Value/Sh0.0010 AUD
Cash/Share0.0010 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.79B
Float1.96B
Insiders37.57%
Institutions0.00%
Technical
SMA 500.0020 AUD
SMA 2000.0025 AUD
Beta-0.64
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)2.16M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—